Small molecules which reverse Rosiglitazone treatment
Canned Analysis
FAIR Metrics
0 evaluations
General Information
AccessionDCA00012447
TitleSmall molecules which reverse Rosiglitazone treatment
DescriptionThe L1000 database was queried in order to identify small molecule perturbations which reverse the gene expression signature induced by Rosiglitazone treatment in the Stromal-vascular cells (PRDM16-deficient inguinal white adipose tissue) cell type.
Analysis URLhttp://amp.pharm.mssm.edu/L1000CDS2/#/result/58d1e957e467bea600fb97c4
Upload DateSeptember 20, 2017
Uploadermaayanlab
Metadata
Analysis Curatorcadimo
CREEDS IDdrug:3267
Cell TypeStromal-vascular cells (PRDM16-deficient inguinal white adipose tissue)
Drug NameRosiglitazone
DrugBank IDDB00412
Organismmouse
SMILES IDO=C1NC(=O)C(S1)Cc1ccc(cc1)OCCN(c1ccccn1)C
L1000CDS2 parameters
Directionreverse
Characteristic Direction parameters
Control SamplesGSM860624, GSM860625
Perturbed SamplesGSM860626, GSM860627
Tools used in the analysis
Dataset Accession
Characteristic Direction
Published March 2014
A geometrical multivariate approach to identify differentially expressed genes
26829
L1000CDS2
Published August 2016
An ultra-fast LINCS L1000 Characteristic Direction signature search engine
7756
Datasets used in the analysis
Keyword
Tool Name
GSE35011
Gene Expression Omnibus
Rosiglitazone effect on PRDM16-deficient inguinal white adipose tissue: stromal-vascular cells
28
FAIR Evaluation
Sorry, you must be signed in to evaluate this object.